PSORIATIC ARTHRITIS

This study looks at whether adding tirzepatide (a weight-loss drug) to the usual psoriatic arthritis treatment ixekizumab helps people with active psoriatic arthritis who are also overweight or obese. About 200 adults will take both drugs for up to 12 months. The goal is to see i…

This study tests whether upadacitinib, a daily pill, can reduce inflammation in the spine and joints of people with active psoriatic arthritis. About 100 adults who have not responded well to standard treatments will receive either the drug or a placebo for 12 weeks. The goal is …

This study explores whether fecal transplants (capsules containing healthy donor stool) can improve quality of life and control inflammation in people newly diagnosed with rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, Crohn's disease, or ulcerative colitis. T…

This study tests a new oral drug called zasocitinib (TAK-279) for adults with active psoriatic arthritis who have not tried biologic treatments. About 1,088 participants will receive either the new drug, an active comparator, or a placebo for up to 60 weeks. The main goal is to s…

This study is for people who have both an autoimmune disorder (like rheumatoid arthritis, lupus, or multiple sclerosis) and advanced cancer that has spread or cannot be removed. It tests a drug called nivolumab, which helps the immune system fight cancer, given alone or with othe…

This study compares two ways of giving the drug bimekizumab to people with active psoriatic arthritis or axial spondyloarthritis: as an IV infusion or a shot under the skin. Researchers want to see if the IV version works just as well as the shot. About 392 adults who are suitabl…

This study follows about 1,200 adults with psoriatic arthritis to see how long they stay on risankizumab compared to other advanced treatments. Participants receive their usual prescribed care, and researchers track treatment persistence and effectiveness over 24 months. The goal…

This study tests whether switching to guselkumab (a different type of biologic) is better than switching to another TNF inhibitor (golimumab) for people with psoriatic arthritis whose first TNF inhibitor stopped working or didn't work well. About 63 adults with active psoriatic a…

This study tests a new medicine called SPY002-072 in adults with moderate-to-severe rheumatoid arthritis, psoriatic arthritis, or axial spondyloarthritis. About 285 participants will receive either the drug or a placebo to see if it reduces joint swelling and pain. The goal is to…

This study tests two drugs, risankizumab and lutikizumab, alone or together, in adults with active psoriatic arthritis (PsA). PsA causes joint pain and swelling due to the immune system attacking healthy tissue. About 120 participants will be randomly assigned to one of three tre…

This study tests a new drug called picankibart for people with active psoriatic arthritis, a condition causing joint pain and skin patches. About 222 adults will get either the drug or a placebo to see if it improves joint swelling and tenderness. The goal is to find the best dos…

This study looks at the long-term safety and effectiveness of the drug zasocitinib for adults with psoriatic arthritis, a condition that causes joint pain and skin problems. Participants who completed a one-year study on this drug can join and will take zasocitinib daily for up t…

This study is testing whether a new oral medication called zasocitinib can help control the symptoms of active psoriatic arthritis, a condition that causes joint pain and skin plaques. About 600 participants will be randomly assigned to receive one of two doses of the drug or a p…

This study tests whether adding two simple questions about morning stiffness and lower back pain to a standard screening tool can help doctors spot psoriatic arthritis earlier in people with moderate-to-severe plaque psoriasis. About 502 adults in Canada who are candidates for bi…

This study tests whether tulisokibart can reduce symptoms like joint pain and swelling in adults with active psoriatic arthritis. About 140 participants will receive either the study drug or a placebo. Researchers will measure improvement at 16 weeks using standard arthritis resp…

This study tests whether an online program that teaches better diet and self-care can reduce fatigue and improve quality of life for adults with rheumatoid arthritis, Sjogren's syndrome, lupus, mixed connective tissue disease, or psoriatic arthritis. About 200 participants will u…

This study is testing a new educational tool designed for people with melanoma who also have an autoimmune disease (like rheumatoid arthritis or Crohn's disease) and may receive immune checkpoint inhibitor drugs. Researchers want to see if the tool is easy to use and helpful for …

This study is creating a large database and biobank from 2200 patients with chronic inflammatory diseases like lupus, multiple sclerosis, and severe asthma. Researchers will track disease activity, quality of life, and treatment responses over time. The goal is to identify new ma…

This study aims to understand why tendons become painful and inflamed in people with psoriatic arthritis. Researchers will take small tissue samples from the Achilles tendon of 30 participants to look for immune cells and inflammatory markers. The goal is to learn more about the …

This study is building a large database and sample bank from 5,000 adults with various rheumatic diseases like rheumatoid arthritis, lupus, and psoriatic arthritis. Researchers will use this information to find links between patient outcomes and biological markers. The goal is to…

This study is creating a biobank of blood and tissue samples from 2,000 people with rheumatoid arthritis, psoriatic arthritis, spondyloarthritis, or osteoporosis. Researchers will analyze these samples to find biological markers that can predict how well a patient will respond to…

This study looks at how much of the drug bimekizumab ends up in the breast milk of mothers who are already taking it for conditions like psoriasis or arthritis. About 20 breastfeeding women will provide milk samples over several weeks. The goal is to understand possible exposure …

This study looks at how bimekizumab changes gene activity in people with moderate to severe plaque psoriasis, with or without psoriatic arthritis. About 90 adults will provide skin samples to measure gene expression changes after 48 weeks of treatment. The goal is to understand h…